Janet Woodcock

Burning Rock Reports First Quarter 2024 Financial Results

Retrieved on: 
星期三, 五月 29, 2024
Consensus, NGS, Diagnosis, Janet Woodcock, Investment, VIE, Travel, Marketing, Growth, Research, WFOE, Depreciation, Biotechnology, ID, Webcast, Nucleic acid thermodynamics

GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024.

Key Points: 
  • GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024.
  • Total value of new contracts during the first quarter of 2024 amounted to RMB218 million, representing a growth over 100% from the same period in 2023.
  • The equity change of Beijing Burning Rock Biotech Limited had been completed, and certain contractual agreements had been amended.
  • The chart below sets forth our corporate structure and identifies our principal subsidiaries as of the date of this release:
    Burning Rock will host a conference call to discuss the first quarter 2024 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on May 29, 2024.

Uni-Bio Science Group Announces 2023 Annual Results

Retrieved on: 
星期三, 四月 10, 2024
Escherichia coli, Gel, Prevalence, FN, Hip, Risk, Patient, Janet Woodcock, EGF, KL1, Yoy, Wound healing, Osteoporosis, CMO, Marketing, Dry eye syndrome, Government, Wrist, Genetic engineering, Ageing, Ophthalmology, Fine chemical

[27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).

Key Points: 
  • [27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).
  • The Group reached a significant milestone with the successful introduction of Skbrella™ FN, marking its entry into the advanced skincare raw material market.
  • In 2023, the Group recorded a revenue of approximately HK$484.7 million, representing an increase of 10.1 % YoY.
  • The Group strictly controlled its general and administrative expenses, which only accounted for 9.8% of revenue in 2023 as compared with 10.7% in 2022.

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

Retrieved on: 
星期二, 十月 17, 2023
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Diagnosis, Incidence, Partnership, 18F, Radiation, PET, Recurrence, Radiopharmaceutical, PSMA, Cancer, Janet Woodcock, Chinese, Prostate cancer, Blue Earth, CSCO, Patient, Medical imaging

It marks an important stage in the Blue Earth Diagnostics’ strategy to make flotufolastat (18F) available to patients and clinicians globally.

Key Points: 
  • It marks an important stage in the Blue Earth Diagnostics’ strategy to make flotufolastat (18F) available to patients and clinicians globally.
  • Yanmin Tang, CEO of Sinotau Pharmaceutical Group, said, “Sinotau Pharmaceutical Group is dedicated to the field of new generation radiopharmaceuticals.
  • We are pleased to form this strategic cooperation with Blue Earth Diagnostics and we look forward to making flotufolastat (18F) available to the clinical community in China.
  • It is engineered to advance clinical decision-making by providing useful information to guide treatment planning in men with prostate cancer.

Octapharma USA Grant Supports PANS/PANDAS Education Event at NHIA Conference March 27 in Washington, D.C.

Retrieved on: 
星期四, 三月 23, 2023
University of Arizona College of Medicine – Tucson, PANS, Janet Woodcock, Sodium chloride, Medical Affairs Bureau, University, Erythema ab igne, Octapharma, Encephalitis, DSM-IV codes, University of Arizona College of Pharmacy, Science, Patient, Immune system, Clutch (eggs), Diagnosis, Research, PANDAS, Conference, Strep, Pharmaceutical industry

The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.

Key Points: 
  • The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.
  • Rice, M.D., both of the University of Arizona College of Medicine Tucson and investigators leading the Octapharma PANS/PANDAS clinical trial.
  • "Octapharma is looking forward to sharing valuable information on PANS/PANDAS with NHIA attendees," said Octapharma USA President Flemming Nielsen.
  • For more study information, please contact Huub Kreuwel, Ph.D., Octapharma USA, Vice President of Scientific and Medical Affairs, at [email protected] or visit ClinicalTrials.gov (Identifier: NCT04508530).

Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update

Retrieved on: 
星期四, 八月 26, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Company, Commercialization, U.S. FDA, COVID-19, Cirrhosis, Enrollment, CANF, Institute of Liver and Biliary Sciences, Cancer, Rheumatoid arthritis, SSC, Liver cancer, Survival, Treatment, Phase, HCC, Research, Corporation, Janet Woodcock, Patent, Animal, Advanced IRB, Cat, NYSE, Psoriasis, Institutional review board, CBD, Development, Ministry, Osteoarthritis, Use, Patient, Dog, NASH, Commencement at Central Connecticut State University, Exercise, TASE, Pharmaceutical industry, Health insurance, Medical device, Cryptocurrency

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2021.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2021.
  • Patient enrollment is expected to commence Q3 2021, ahead of the prior expected start date of Q4 2021.
  • Financial income, net for the six months ended June 30, 2021 was $0.20 million compared to financial expense, net of $0.12 million for the same period in 2020.
  • The Company's consolidated financial results for the six months ended June 30, 2021 are presented in accordance with US GAAP Reporting Standards.

New Horizon Health Announces 2021 Interim Results: Revenue Increases 317% Year-on-year, Gross Profit Margin Climbs to 56.2%

Retrieved on: 
星期六, 八月 21, 2021
People, National Health Commission, Diagnosis, National Medical Products Administration, Health, Research, Awareness, Hospital, Nationwide, Partnership, Colorectal cancer, Breast cancer, PICA, IARC, No, Health care, DNA, Epigenomics, Janet Woodcock, Committee, Chinese, Investment, Molecular Cancer Research, Clinical trial, National Cancer Center, CEO, Genetic testing, International Agency for Research on Cancer, Extrapyramidal system, Technology, Industry, Colonoscopy, American Society of Clinical Oncology, NPV, Large intestine, Guideline, Hong Kong Stock Exchange, Pharmacy, Fund, NMPA, Organic, Epigenomics AG, ISO13485, US, Company, Growth, City, Stock exchange, Treatment, Marketing, Attention, FIT, Compliance, CSCO, Pharmaceutical industry, Mobile phone, Oil

Gross profit margin also climbed from 21.3% in the same period of 2020 to 56.2%.

Key Points: 
  • Gross profit margin also climbed from 21.3% in the same period of 2020 to 56.2%.
  • The product's gross profit margin also increased from 26.4% in the same period of 2020 to 59.0%.
  • As progress relies on strength, New Horizon Health has just opened a new chapter of growth.
  • During the 618 Festival, New Horizon Health teamed with Kuaishou Health and Xiaohe Health to launch a popular science short video campaign featuring intestinal health, early screening, and cancer prevention.

Drs Janet Woodcock and Laura Esserman Confirmed to Speak on A Vision for the Integration of Clinical Research and Care at CRAACO, organized by the Conference Forum

Retrieved on: 
星期四, 四月 15, 2021
Drug policy of the United States, Janet Woodcock, Clinical

b'NEW YORK, April 15, 2021 /PRNewswire-PRWeb/ --The Conference Forum announced that Drs Janet Woodcock, acting FDA Commissioner and Laura Esserman, Director, UCSF Carol Franc Buck Breast Cancer Center, are confirmed in a joint keynote discussion at the upcoming 2021 CRAACO virtual meeting, April 26th at 11:45am ET.\nDrs Woodcock and Esserman will discuss the tools, models and mindsets to integrate and improve the quality of clinical research and clinical care while reducing the burden for trial participation.\nDr Woodcock has long been a strong advocate for bridging the gap between clinical research and clinical care to allow more patients to have access to clinical research options.

Key Points: 
  • b'NEW YORK, April 15, 2021 /PRNewswire-PRWeb/ --The Conference Forum announced that Drs Janet Woodcock, acting FDA Commissioner and Laura Esserman, Director, UCSF Carol Franc Buck Breast Cancer Center, are confirmed in a joint keynote discussion at the upcoming 2021 CRAACO virtual meeting, April 26th at 11:45am ET.\nDrs Woodcock and Esserman will discuss the tools, models and mindsets to integrate and improve the quality of clinical research and clinical care while reducing the burden for trial participation.\nDr Woodcock has long been a strong advocate for bridging the gap between clinical research and clinical care to allow more patients to have access to clinical research options.
  • During a recent National Academies of Sciences, Engineering and Medicine (NASEM) workshop in early 2021 , Dr Woodcock called for a renewed effort putting clinical research into community sites, to accelerate research and prepare for the next global health crisis.\nWhile these smaller community sites don\'t have the same research infrastructure that academic medical centers do, Dr Woodcock told attendees that, "Community sites, we learned during this pandemic, can be supported by specialized CROs or other organizations that supply the education and expertise to enable clinical research.
  • They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.
  • They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high-quality networking.\n'

Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants

Retrieved on: 
星期一, 二月 22, 2021
Drug policy of the United States, Janet Woodcock, Food and Drug Administration, COVID-19 testing, Medicine, Health care, Health in the United States

"The FDA is committed to identifying efficient ways to modify medical products that either are in the pipeline or have been authorized for emergency use to address emerging variants," said Acting FDA Commissioner Janet Woodcock, M.D.

Key Points: 
  • "The FDA is committed to identifying efficient ways to modify medical products that either are in the pipeline or have been authorized for emergency use to address emerging variants," said Acting FDA Commissioner Janet Woodcock, M.D.
  • We need to arm health care providers with the best available diagnostics, therapeutics and vaccines to fight this virus.
  • As with any evolving situation, the FDA will be continuously monitoring the situation and updating its plans as more information becomes available.
  • The FDA issued a new guidance for test developers, Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests .

Statement of the National Alliance for Hispanic Health on selection of Janet Woodcock, MD as Acting Commissioner of the US Food and Drug Administration (FDA)

Retrieved on: 
星期四, 一月 21, 2021
Food and Drug Administration, United States Public Health Service, Janet Woodcock, COVID-19 vaccine, Health sciences, Medicine, Health, Presidency of Donald Trump

Today, the nation's COVID-19 vaccine and therapeutics review and approval effort will be in the hands of one of our nation's most experienced and skilled health leaders.

Key Points: 
  • Today, the nation's COVID-19 vaccine and therapeutics review and approval effort will be in the hands of one of our nation's most experienced and skilled health leaders.
  • The critical FDA infrastructure is well served by naming Dr. Janet Woodcock as the Acting Commissioner of FDA.
  • She has a deep understanding and deep empathy for the needs of those most underserved by our health system.
  • The Alliance is the nation's foremost science-based source of information and trusted advocate for the health of Hispanics in the United States with a mission to achieve the best health for all.